INTERESTED IN THIS RESEARCH?
Contact our analysts for inquiries, samples, and expert insights.
REPORT OUTLOOK
| Market Size | CAGR | Dominating Region |
|---|---|---|
| USD 24.06 billion by 2029 | 8.9 % | Asia-Pacific |
| by Type | by Treatment Type | by Route of Administration |
|---|---|---|
|
|
|
SCOPE OF THE REPORT
Leukemia Therapeutics Market Overview
The global leukemia therapeutics market is projected to reach USD 24.06 billion by 2029 from USD 12.20 billion in 2020, at a CAGR of 8.9 % from 2022 to 2029.
Leukemia is a type of blood cancer that affects the bone marrow and blood cells. It is a complex disease that can be difficult to treat, but there are various leukemia therapeutics available to help manage the disease and improve patient outcomes.
Leukemia therapeutics include chemotherapy, radiation therapy, targeted therapy, immunotherapy, and stem cell transplant. Chemotherapy involves the use of drugs to kill cancer cells, while radiation therapy uses high-energy radiation to kill cancer cells. Targeted therapy involves drugs that specifically target cancer cells, while immunotherapy involves stimulating the patient’s immune system to attack cancer cells. Stem cell transplant involves the replacement of the patient’s bone marrow with healthy stem cells.
The goal of leukemia therapeutics is to eliminate cancer cells from the body and achieve remission, while also preserving quality of life and minimizing side effects. The choice of treatment depends on a variety of factors, including the type and stage of leukemia, the patient’s age and overall health, and the specific characteristics of the cancer cells.
There is an increasing need for more effective treatments for leukemia due to its continued prevalence as a significant health concern. As a result, there has been an emergence of new therapies like tyrosine kinase inhibitors, which are designed to target specific genes and proteins that contribute to the growth and spread of leukemia cells. In addition, there is a growing awareness of leukemia and its treatment options, which has resulted in a rising demand for chemotherapy and targeted therapy drugs. The growth of the leukemia therapeutics market is also driven by the increase in healthcare spending on a global scale. Personalized medicine is receiving more attention, and the development of new diagnostic tools has led to a growing demand for targeted treatments that can be tailored to individual patients.
The high cost of many leukemia treatments can restrict patient access to these therapies. The market growth may also be hampered by the introduction of generic drugs that can lower the prices of treatments, as well as regulatory requirements that are both time-consuming and expensive. This rigorous regulatory environment can slow down the development of new treatments and approvals, limiting the speed of innovation and market growth. Overall, these factors serve as restraints on the leukemia therapeutics market.
The leukemia therapeutics market is expected to experience significant growth opportunities due to the ongoing development of innovative treatments, including immunotherapy and targeted therapy. Key players in the industry are increasingly obtaining product approvals for their leukemia therapeutics, which is anticipated to have a positive impact on market growth. These advancements are likely to result in a more favorable market landscape and create promising opportunities for future growth.
| ATTRIBUTE | DETAILS |
| Study period | 2022-2029 |
| Base year | 2022 |
| Estimated year | 2023 |
| Forecasted year | 2023-2029 |
| Historical period | 2018-2022 |
| Unit | Value (USD Billion) |
| Segmentation | By Product, By Treatment, By Route of Administration, By Distribution Channel, By Region |
| By Type |
|
| By Treatment |
|
| By Route of Administration |
|
| By Distribution Channel |
|
| By Region |
|
Leukemia Therapeutics Market Segment Analysis
The global leukemia therapeutics market is segmented by type, treatment type, route of administration, distribution channel and region.
Based on type, the leukemia therapeutics market is segmented into Chronic Myeloid Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL), Acute Myeloid Leukemia (AML), Others. The chronic myeloid segment is predicted to grow rapidly due to its high prevalence, the quick adoption of tyrosine kinase inhibitors, and an increase in the use of drugs during the forecasted period. Furthermore, the market segment’s growth during the projected period is fueled by increased awareness of the disease and ongoing research and development activities. The market for CML therapeutics is driven by the rising incidence of the disease globally, increasing research and development activities, and growing demand for targeted therapies that can specifically address the genetic abnormalities causing the disease.
Based on treatment type, the leukemia therapeutics market is classified into chemotherapy, targeted therapy, immunotherapy, others. The leukemia therapeutics market is expected to be dominated by the chemotherapy segment, as it is the primary treatment option for leukemia and has been found to be effective in achieving positive treatment outcomes for patients during the forecasted period. Targeted therapy is a relatively newer treatment option for leukemia that targets specific proteins or genes that are involved in the growth and spread of cancer cells. It is often used in combination with chemotherapy and has shown promising results in the treatment of certain types of leukemia. However, chemotherapy remains the most widely used treatment option for leukemia and is likely to continue to dominate the market in terms of revenue. Immunotherapy is also expected to grow rapidly due to the promising results seen in clinical trials.
Based on route of administration, the leukemia therapeutics market is classified into Oral, Injectable. The injectable segment is the leading category in the leukemia therapeutics market, mainly as a significant number of drugs utilized in leukemia treatment are available in injectable forms like chemotherapy and targeted therapy. The injectable route of administration is preferred since it is highly effective. Injectable drugs are quickly absorbed by the body, providing swift results. This factor boosts their acceptance among patients and healthcare professionals. The oral segment also expected to dominate the market during the forecast period due to the convenience and ease of administration of oral medications. Patients are more likely to comply with oral medication regimens, which leads to better treatment outcomes.
Based on distribution channel, the leukemia therapeutics market is segmented into hospital pharmacy, retail pharmacy, others. The hospital pharmacy segment is estimated to account for the biggest share of the worldwide market in the forecast period. The major source of therapy is hospitals. Patients visit hospitals for the diagnosis and treatment of various ailments, which leads in the rise of hospital pharmacies. The retail pharmacy category is estimated to account for the second-largest market share over the projection period. The presence of a small number of retail pharmacies selling leukaemia treatment products in developing countries has resulted in its second-place distribution channel ranking.
Leukemia Therapeutics Market Players
The global leukemia therapeutics market key players include Novartis AG, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Pfizer Inc., AbbVie Inc., Amgen Inc., Sanofi, AstraZeneca plc, Astellas Pharma Inc., Johnson & Johnson Services, Inc., Takeda Pharmaceutical, Lupin Ltd., Gilead Sciences
Industry Developments:
MAY 03, 2023: Bristol Myers Squibb announced that the European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
April 6, 2023: AbbVie announced the intent to voluntarily withdraw, in the U.S., accelerated IMBRUVICA® (ibrutinib) approvals for patients with the blood cancers mantle cell lymphoma (MCL) who have received at least one prior therapy and with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.
Who Should Buy? Or Key stakeholders
- Pharmaceutical and biotechnology companies
- Academic and research institutes
- Leukemia Therapeutics Manufacturers and Vendors
- Government regulatory authorities
- Investors and venture capitalists
- Cancer Organization and Association
- Medical device manufacturers
- Healthcare providers and distributors
- Insurance companies
Leukemia Therapeutics Market Regional Analysis
The leukemia therapeutics market by region includes North America, Asia-Pacific (APAC), Europe, South America, and Middle East & Africa (MEA).
- North America: includes the US, Canada, Mexico
- Asia Pacific: includes China, Japan, South Korea, India, Australia, ASEAN and Rest of APAC
- Europe: includes UK, Germany, France, Italy, Spain, Russia, and Rest of Europe
- South America: includes Brazil, Argentina and Rest of South America
- Middle East & Africa: includes Turkey, UAE, Saudi Arabia, South Africa, and Rest of MEA
North America held the largest share of the market owing to the high prevalence of leukemia, increased funding for R&D, and rising awareness about cancer. Furthermore, the presence of key players in the region and high healthcare expenditure contribute to the growth of the market. Europe is the second-largest market, with the increasing prevalence of leukemia, rising demand for effective treatments, and the presence of key players contributing to the market’s growth. In addition, the growing awareness about leukemia and increasing focus on personalized medicine have led to the development of targeted treatments, further fueling market growth.
The Asia-Pacific region is expected to witness significant growth during the forecast period. This can be attributed to the increasing prevalence of leukemia in the region, coupled with the rising healthcare expenditure and growing awareness about the disease. Furthermore, the presence of a large patient pool and improving healthcare infrastructure in the region are expected to further drive the market growth.
Key Market Segments: Leukemia Therapeutics Market
Leukemia Therapeutics Market by Type 2022-2029, (USD Billion)
- Chronic Myeloid Leukemia (CML)
- Chronic Lymphocytic Leukemia (CLL)
- Acute Lymphocytic Leukemia (ALL)
- Acute Myeloid Leukemia (AML)
- Others
Leukemia Therapeutics Market by Treatment Type, 2022-2029, (USD Billion)
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Others
Leukemia Therapeutics Market by Route of Administration, 2022-2029, (USD Billion)
- Oral
- Injectable
Leukemia Therapeutics Market by Distribution Channel, 2022-2029, (USD Billion)
- Hospital Pharmacy
- Retail Pharmacy
- Others
Leukemia Therapeutics Market by Regions, 2022-2029, (USD Billion)
- North America
- Europe
- Asia Pacific
- South America
- Middle East and Africa
Important Countries in All Regions Are Covered
Exactitude Consultancy Services Key Objectives:
- Increasing sales and market share
- Developing new technology
- Improving profitability
- Entering new markets
- Enhancing brand reputation
Key Question Answered
- What is the expected growth rate of the leukemia therapeutics market over the next 7 years?
- Who are the major players in the leukemia therapeutics market and what is their market share?
- What are the end-user industries driving demand for the market and what is their outlook?
- What are the opportunities for growth in emerging markets such as Asia-Pacific, Middle East, and Africa?
- How is the economic environment affecting the leukemia therapeutics market, including factors such as interest rates, inflation, and exchange rates?
- What is the expected impact of government policies and regulations on the leukemia therapeutics market?
- What is the current and forecasted size and growth rate of the global leukemia therapeutics market?
- What are the key drivers of growth in the leukemia therapeutics market?
- What are the distribution channels and supply chain dynamics in the leukemia therapeutics market?
- What are the technological advancements and innovations in the leukemia therapeutics market and their impact on product development and growth?
- What are the regulatory considerations and their impact on the market?
- What are the challenges faced by players in the leukemia therapeutics market and how are they addressing these challenges?
- What are the opportunities for growth and expansion in the leukemia therapeutics market?
- What are the service offerings and specifications of leading players in the market?
Table of Content
- INTRODUCTION
- MARKET DEFINITION
- MARKET SEGMENTATION
- RESEARCH TIMELINES
- ASSUMPTIONS AND LIMITATIONS
- RESEARCH METHODOLOGY
- DATA MINING
- SECONDARY RESEARCH
- PRIMARY RESEARCH
- SUBJECT-MATTER EXPERTS’ ADVICE
- QUALITY CHECKS
- FINAL REVIEW
- DATA TRIANGULATION
- BOTTOM-UP APPROACH
- TOP-DOWN APPROACH
- RESEARCH FLOW
- DATA SOURCES
- DATA MINING
- EXECUTIVE SUMMARY
- MARKET OVERVIEW
- GLOBAL LEUKEMIA THERAPEUTICS MARKET OUTLOOK
- MARKET DRIVERS
- MARKET RESTRAINTS
- MARKET OPPORTUNITIES
- IMPACT OF COVID-19 ON LEUKEMIA THERAPEUTICS MARKET
- PORTER’S FIVE FORCES MODEL
- THREAT FROM NEW ENTRANTS
- THREAT FROM SUBSTITUTES
- BARGAINING POWER OF SUPPLIERS
- BARGAINING POWER OF CUSTOMERS
- DEGREE OF COMPETITION
- INDUSTRY VALUE CHAIN ANALYSIS
- GLOBAL LEUKEMIA THERAPEUTICS MARKET OUTLOOK
- GLOBAL LEUKEMIA THERAPEUTICS MARKET BY TYPE, 2020-2029, (USD BILLION)
- CHRONIC MYELOID LEUKEMIA (CML)
- CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
- ACUTE LYMPHOCYTIC LEUKEMIA (ALL)
- ACUTE MYELOID LEUKEMIA (AML)
- OTHERS
- GLOBAL LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE, 2020-2029, (USD BILLION)
- CHEMOTHERAPY
- TARGETED THERAPY
- IMMUNOTHERAPY
- OTHERS
- GLOBAL LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION, 2020-2029, (USD BILLION)
- ORAL
- INJECTABLE
- GLOBAL LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL, 2020-2029, (USD BILLION)
- HOSPITAL PHARMACY
- RETAIL PHARMACY
- OTHERS
- GLOBAL LEUKEMIA THERAPEUTICS MARKET BY REGION, 2020-2029, (USD BILLION)
- NORTH AMERICA
- US
- CANADA
- MEXICO
- SOUTH AMERICA
- BRAZIL
- ARGENTINA
- COLOMBIA
- REST OF SOUTH AMERICA
- EUROPE
- GERMANY
- UK
- FRANCE
- ITALY
- SPAIN
- RUSSIA
- REST OF EUROPE
- ASIA PACIFIC
- INDIA
- CHINA
- JAPAN
- SOUTH KOREA
- AUSTRALIA
- SOUTH-EAST ASIA
- REST OF ASIA PACIFIC
- MIDDLE EAST AND AFRICA
- UAE
- SAUDI ARABIA
- SOUTH AFRICA
- REST OF MIDDLE EAST AND AFRICA
- NORTH AMERICA
- COMPANY PROFILES* BUSINESS OVERVIEW, COMPANY SNAPSHOT, PRODUCT OFFERED, RECENT DEVELOPMENTS)
10.1. NOVARTIS AG
10.2. F. HOFFMANN-LA ROCHE LTD.
10.3. BRISTOL-MYERS SQUIBB COMPANY
10.4. PFIZER INC.
10.5. ABBVIE INC.
10.6. AMGEN INC.
10.7. SANOFI
10.8. ASTRAZENECA PLC
10.9. ASTELLAS PHARMA INC.
10.10. JOHNSON & JOHNSON SERVICES, INC.
10.11. TAKEDA PHARMACEUTICAL
10.12. LUPIN LTD.
10.13. GILEAD SCIENCESÂ *THE COMPANY LIST IS INDICATIVE
LIST OF TABLES
TABLE 1Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â GLOBAL LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 2Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â GLOBAL LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 3Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â GLOBAL LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 4Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â GLOBAL LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 5Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â GLOBAL LEUKEMIA THERAPEUTICS MARKET BY REGION (USD BILLION) 2020-2029
TABLE 6Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET BY COUNTRY (USD BILLION) 2020-2029
TABLE 7Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 8Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 9Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 10Â Â Â Â Â Â Â Â Â Â Â Â Â NORTH AMERICA LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 11Â Â Â Â Â Â Â Â Â Â Â Â Â US LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 12Â Â Â Â Â Â Â Â Â Â Â Â Â US LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 13Â Â Â Â Â Â Â Â Â Â Â Â Â US LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 14Â Â Â Â Â Â Â Â Â Â Â Â Â US LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 15Â Â Â Â Â Â Â Â Â Â Â Â Â CANADA LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 16Â Â Â Â Â Â Â Â Â Â Â Â Â CANADA LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 17Â Â Â Â Â Â Â Â Â Â Â Â Â CANADA LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 18Â Â Â Â Â Â Â Â Â Â Â Â Â CANADA LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 19Â Â Â Â Â Â Â Â Â Â Â Â Â MEXICO LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 20Â Â Â Â Â Â Â Â Â Â Â Â Â MEXICO LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 21Â Â Â Â Â Â Â Â Â Â Â Â Â MEXICO LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 22Â Â Â Â Â Â Â Â Â Â Â Â Â MEXICO LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 23Â Â Â Â Â Â Â Â Â Â Â Â Â SOUTH AMERICA LEUKEMIA THERAPEUTICS MARKET BY COUNTRY (USD BILLION) 2020-2029
TABLE 24Â Â Â Â Â Â Â Â Â Â Â Â Â SOUTH AMERICA LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 25Â Â Â Â Â Â Â Â Â Â Â Â Â SOUTH AMERICA LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 26Â Â Â Â Â Â Â Â Â Â Â Â Â SOUTH AMERICA LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 27Â Â Â Â Â Â Â Â Â Â Â Â Â SOUTH AMERICA LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 28Â Â Â Â Â Â Â Â Â Â Â Â Â BRAZIL LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 29Â Â Â Â Â Â Â Â Â Â Â Â Â BRAZIL LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 30Â Â Â Â Â Â Â Â Â Â Â Â Â BRAZIL LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 31Â Â Â Â Â Â Â Â Â Â Â Â Â BRAZIL LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 32Â Â Â Â Â Â Â Â Â Â Â Â Â ARGENTINA LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 33Â Â Â Â Â Â Â Â Â Â Â Â Â ARGENTINA LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 34Â Â Â Â Â Â Â Â Â Â Â Â Â ARGENTINA LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 35Â Â Â Â Â Â Â Â Â Â Â Â Â ARGENTINA LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 36Â Â Â Â Â Â Â Â Â Â Â Â Â COLOMBIA LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 37Â Â Â Â Â Â Â Â Â Â Â Â Â COLOMBIA LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 38Â Â Â Â Â Â Â Â Â Â Â Â Â COLOMBIA LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 39Â Â Â Â Â Â Â Â Â Â Â Â Â COLOMBIA LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 40Â Â Â Â Â Â Â Â Â Â Â Â Â REST OF SOUTH AMERICA LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 41Â Â Â Â Â Â Â Â Â Â Â Â Â REST OF SOUTH AMERICA LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 42Â Â Â Â Â Â Â Â Â Â Â Â Â REST OF SOUTH AMERICA LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 43Â Â Â Â Â Â Â Â Â Â Â Â Â REST OF SOUTH AMERICA LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 44Â Â Â Â Â Â Â Â Â Â Â Â Â ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET BY COUNTRY (USD BILLION) 2020-2029
TABLE 45Â Â Â Â Â Â Â Â Â Â Â Â Â ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 46Â Â Â Â Â Â Â Â Â Â Â Â Â ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 47Â Â Â Â Â Â Â Â Â Â Â Â Â ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 48Â Â Â Â Â Â Â Â Â Â Â Â Â ASIA-PACIFIC LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 49Â Â Â Â Â Â Â Â Â Â Â Â Â INDIA LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 50Â Â Â Â Â Â Â Â Â Â Â Â Â INDIA LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 51Â Â Â Â Â Â Â Â Â Â Â Â Â INDIA LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 52Â Â Â Â Â Â Â Â Â Â Â Â Â INDIA LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 53Â Â Â Â Â Â Â Â Â Â Â Â Â CHINA LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 54Â Â Â Â Â Â Â Â Â Â Â Â Â CHINA LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 55Â Â Â Â Â Â Â Â Â Â Â Â Â CHINA LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 56Â Â Â Â Â Â Â Â Â Â Â Â Â CHINA LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 57Â Â Â Â Â Â Â Â Â Â Â Â Â JAPAN LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 58Â Â Â Â Â Â Â Â Â Â Â Â Â JAPAN LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 59Â Â Â Â Â Â Â Â Â Â Â Â Â JAPAN LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 60Â Â Â Â Â Â Â Â Â Â Â Â Â JAPAN LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 61Â Â Â Â Â Â Â Â Â Â Â Â Â SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 62Â Â Â Â Â Â Â Â Â Â Â Â Â SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 63Â Â Â Â Â Â Â Â Â Â Â Â Â SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 64Â Â Â Â Â Â Â Â Â Â Â Â Â SOUTH KOREA LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 65Â Â Â Â Â Â Â Â Â Â Â Â Â AUSTRALIA LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 66Â Â Â Â Â Â Â Â Â Â Â Â Â AUSTRALIA LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 67Â Â Â Â Â Â Â Â Â Â Â Â Â AUSTRALIA LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 68Â Â Â Â Â Â Â Â Â Â Â Â Â AUSTRALIA LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 69Â Â Â Â Â Â Â Â Â Â Â Â Â SOUTH-EAST ASIA LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 70Â Â Â Â Â Â Â Â Â Â Â Â Â SOUTH-EAST ASIA LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 71Â Â Â Â Â Â Â Â Â Â Â Â Â SOUTH-EAST ASIA LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 72Â Â Â Â Â Â Â Â Â Â Â Â Â SOUTH-EAST ASIA LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 73Â Â Â Â Â Â Â Â Â Â Â Â Â REST OF ASIA PACIFIC LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 74Â Â Â Â Â Â Â Â Â Â Â Â Â REST OF ASIA PACIFIC LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 75Â Â Â Â Â Â Â Â Â Â Â Â Â REST OF ASIA PACIFIC LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 76Â Â Â Â Â Â Â Â Â Â Â Â Â REST OF ASIA PACIFIC LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 77Â Â Â Â Â Â Â Â Â Â Â Â Â EUROPE LEUKEMIA THERAPEUTICS MARKET BY COUNTRY (USD BILLION) 2020-2029
TABLE 78Â Â Â Â Â Â Â Â Â Â Â Â Â EUROPE LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 79Â Â Â Â Â Â Â Â Â Â Â Â Â EUROPE LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 80Â Â Â Â Â Â Â Â Â Â Â Â Â EUROPE LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 81Â Â Â Â Â Â Â Â Â Â Â Â Â EUROPE LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 82Â Â Â Â Â Â Â Â Â Â Â Â Â GERMANY LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 83Â Â Â Â Â Â Â Â Â Â Â Â Â GERMANY LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 84Â Â Â Â Â Â Â Â Â Â Â Â Â GERMANY LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 85Â Â Â Â Â Â Â Â Â Â Â Â Â GERMANY LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 86Â Â Â Â Â Â Â Â Â Â Â Â Â UK LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 87Â Â Â Â Â Â Â Â Â Â Â Â Â UK LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 88Â Â Â Â Â Â Â Â Â Â Â Â Â UK LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 89Â Â Â Â Â Â Â Â Â Â Â Â Â UK LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 90Â Â Â Â Â Â Â Â Â Â Â Â Â FRANCE LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 91Â Â Â Â Â Â Â Â Â Â Â Â Â FRANCE LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 92Â Â Â Â Â Â Â Â Â Â Â Â Â FRANCE LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 93Â Â Â Â Â Â Â Â Â Â Â Â Â FRANCE LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 94Â Â Â Â Â Â Â Â Â Â Â Â Â ITALY LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 95Â Â Â Â Â Â Â Â Â Â Â Â Â ITALY LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 96Â Â Â Â Â Â Â Â Â Â Â Â Â ITALY LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 97Â Â Â Â Â Â Â Â Â Â Â Â Â ITALY LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 98Â Â Â Â Â Â Â Â Â Â Â Â Â SPAIN LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 99Â Â Â Â Â Â Â Â Â Â Â Â Â SPAIN LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 100Â Â Â Â Â Â Â Â Â Â Â SPAIN LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 101Â Â Â Â Â Â Â Â Â Â Â SPAIN LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 102Â Â Â Â Â Â Â Â Â Â Â RUSSIA LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 103Â Â Â Â Â Â Â Â Â Â Â RUSSIA LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 104Â Â Â Â Â Â Â Â Â Â Â RUSSIA LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 105Â Â Â Â Â Â Â Â Â Â Â RUSSIA LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 106Â Â Â Â Â Â Â Â Â Â Â REST OF EUROPE LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 107Â Â Â Â Â Â Â Â Â Â Â REST OF EUROPE LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 108Â Â Â Â Â Â Â Â Â Â Â REST OF EUROPE LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 109Â Â Â Â Â Â Â Â Â Â Â REST OF EUROPE LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 110Â Â Â Â Â Â Â Â Â Â Â MIDDLE EAST AND AFRICA LEUKEMIA THERAPEUTICS MARKET BY COUNTRY (USD BILLION) 2020-2029
TABLE 111Â Â Â Â Â Â Â Â Â Â Â MIDDLE EAST AND AFRICA LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 112Â Â Â Â Â Â Â Â Â Â Â MIDDLE EAST AND AFRICA LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 113Â Â Â Â Â Â Â Â Â Â Â MIDDLE EAST AND AFRICA LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 114Â Â Â Â Â Â Â Â Â Â Â MIDDLE EAST AND AFRICA LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 115Â Â Â Â Â Â Â Â Â Â Â UAE LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 116Â Â Â Â Â Â Â Â Â Â Â UAE LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 117Â Â Â Â Â Â Â Â Â Â Â UAE LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 118Â Â Â Â Â Â Â Â Â Â Â UAE LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 119Â Â Â Â Â Â Â Â Â Â Â SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 120Â Â Â Â Â Â Â Â Â Â Â SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 121Â Â Â Â Â Â Â Â Â Â Â SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 122Â Â Â Â Â Â Â Â Â Â Â SAUDI ARABIA LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 123Â Â Â Â Â Â Â Â Â Â Â SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 124Â Â Â Â Â Â Â Â Â Â Â SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 125Â Â Â Â Â Â Â Â Â Â Â SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 126Â Â Â Â Â Â Â Â Â Â Â SOUTH AFRICA LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
TABLE 127Â Â Â Â Â Â Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
TABLE 128Â Â Â Â Â Â Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
TABLE 129Â Â Â Â Â Â Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
TABLE 130Â Â Â Â Â Â Â Â Â Â Â REST OF MIDDLE EAST AND AFRICA LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
LIST OF FIGURESÂ
FIGURE 1Â Â Â Â Â Â Â Â Â Â Â Â Â MARKET DYNAMICS
FIGURE 2Â Â Â Â Â Â Â Â Â Â Â Â Â MARKET SEGMENTATION
FIGURE 3Â Â Â Â Â Â Â Â Â Â Â Â Â REPORT TIMELINES: YEARS CONSIDERED
FIGURE 4Â Â Â Â Â Â Â Â Â Â Â Â Â DATA TRIANGULATION
FIGURE 5Â Â Â Â Â Â Â Â Â Â Â Â Â BOTTOM-UP APPROACH
FIGURE 6Â Â Â Â Â Â Â Â Â Â Â Â Â TOP-DOWN APPROACH
FIGURE 7Â Â Â Â Â Â Â Â Â Â Â Â Â RESEARCH FLOW
FIGURE 8Â Â Â Â Â Â Â Â Â Â Â Â Â GLOBAL LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2020-2029
FIGURE 9Â Â Â Â Â Â Â Â Â Â Â Â Â GLOBAL LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2020-2029
FIGURE 10Â Â Â Â Â Â Â Â Â Â GLOBAL LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2020-2029
FIGURE 11Â Â Â Â Â Â Â Â Â Â GLOBAL LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2020-2029
FIGURE 12Â Â Â Â Â Â Â Â Â Â GLOBAL LEUKEMIA THERAPEUTICS MARKET BY REGION (USD BILLION) 2020-2029
FIGURE 13          PORTER’S FIVE FORCES MODEL
FIGURE 14Â Â Â Â Â Â Â Â Â Â GLOBAL LEUKEMIA THERAPEUTICS MARKET BY TYPE (USD BILLION) 2021
FIGURE 15Â Â Â Â Â Â Â Â Â Â GLOBAL LEUKEMIA THERAPEUTICS MARKET BY TREATMENT TYPE (USD BILLION) 2021
FIGURE 16Â Â Â Â Â Â Â Â Â Â GLOBAL LEUKEMIA THERAPEUTICS MARKET BY ROUTE OF ADMINISTRATION (USD BILLION) 2021
FIGURE 17Â Â Â Â Â Â Â Â Â Â GLOBAL LEUKEMIA THERAPEUTICS MARKET BY DISTRIBUTION CHANNEL (USD BILLION) 2021
FIGURE 18Â Â Â Â Â Â Â Â Â Â GLOBAL LEUKEMIA THERAPEUTICS MARKET BY REGION (USD BILLION) 2021
FIGURE 19Â Â Â Â Â Â Â Â Â Â MARKET SHARE ANALYSIS
FIGURE 20Â Â Â Â Â Â Â Â Â Â NOVARTIS AG: COMPANY SNAPSHOT
FIGURE 21Â Â Â Â Â Â Â Â Â Â F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
FIGURE 22Â Â Â Â Â Â Â Â Â Â BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
FIGURE 23Â Â Â Â Â Â Â Â Â Â PFIZER INC.: COMPANY SNAPSHOT
FIGURE 24Â Â Â Â Â Â Â Â Â Â ABBVIE INC.: COMPANY SNAPSHOT
FIGURE 25Â Â Â Â Â Â Â Â Â Â AMGEN INC.: COMPANY SNAPSHOT
FIGURE 26Â Â Â Â Â Â Â Â Â Â SANOFI: COMPANY SNAPSHOT
FIGURE 27Â Â Â Â Â Â Â Â Â Â ASTRAZENECA PLC: COMPANY SNAPSHOT
FIGURE 28Â Â Â Â Â Â Â Â Â Â ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
FIGURE 29Â Â Â Â Â Â Â Â Â Â JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT
FIGURE 30Â Â Â Â Â Â Â Â Â Â TAKEDA PHARMACEUTICAL: COMPANY SNAPSHOT
FIGURE 31Â Â Â Â Â Â Â Â Â Â LUPIN LTD.: COMPANY SNAPSHOT
FIGURE 32Â Â Â Â Â Â Â Â Â Â GILEAD SCIENCES: COMPANY SNAPSHOT
FAQ
The global leukemia therapeutics market is projected to reach USD 24.06 billion by 2029 from USD 12.20 billion in 2020, at a CAGR of 8.9 % from 2022 to 2029.
The global leukemia therapeutics market registered a CAGR of 8.9 % from 2022 to 2029.
The increasing prevalence of leukemia, a large patient population, and increasing product launches for leukemia are the major factors driving the growth of the market.
In-Depth Database
Our Report’s database covers almost all topics of all regions over the Globe.
Recognised Publishing Sources
Tie ups with top publishers around the globe.
Customer Support
Complete pre and post sales
support.
Safe & Secure
Complete secure payment
process.